文献速递帕金森病与运动障碍

血液神经丝轻链蛋白:帕金森综合征鉴别诊断的生物标志物

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
PubMed 文献 · Neurology · 2017-02-08

研究纳入3个独立前瞻性队列(Lund n=278、London n=117及早期病程队列 n=109),评估血液NfL区分帕金森病(PD)与非典型帕金森综合征(APD)的诊断准确性。结果显示血与脑脊液NfL强相关(ρ≥0.73-0.84,p≤0.001),APD组血NfL较PD及健康对照升高(p<0.001),区分PD与APD的AUC在Lund队列为0.91、London队列0.85、早期队列0.81。

要点

  • 血NfL与脑脊液NfL强相关,可替代脑脊液检测用于鉴别PD与APD。
  • MSA、PSP、CBS患者血NfL均高于PD患者及健康对照。
  • 血NfL区分PD与APD的AUC在0.81-0.91之间,早期病程患者同样适用。

核心结论

  • 定量检测血液NfL浓度可用于区分帕金森病与非典型帕金森综合征。
  • 血液NfL有望纳入初级保健和专科诊所帕金森症状患者的诊断检查流程。

研究设计与样本

  • 研究纳入3个独立前瞻性队列:Lund队列(n=278)、London队列(n=117)及早期病程队列(n=109)。
  • 队列包含健康对照及PD、进行性核上性麻痹(PSP)、皮质基底节综合征(CBS)、多系统萎缩(MSA)患者。
  • 早期病程队列纳入病程≤3年的PD、PSP、MSA或CBS患者。
  • 采用超灵敏单分子阵列(Simoa)方法测量血NfL浓度,评估区分PD与APD的诊断准确性。

主要发现

  • 血与脑脊液NfL浓度呈强相关(ρ≥0.73-0.84,p≤0.001)。
  • 在所有队列中,MSA、PSP和CBS(即所有APD组)患者血NfL较PD患者及健康对照升高(p<0.001)。
  • Lund队列中血NfL区分PD与APD的AUC为0.91。
  • London队列中血NfL区分PD与APD的AUC为0.85。
  • 早期病程队列中血NfL区分PD与APD的AUC为0.81。

关键数值与推荐

  • 血NfL区分PD与APD的AUC:Lund队列0.91,London队列0.85,早期病程队列0.81。
  • 血与脑脊液NfL相关系数ρ≥0.73-0.84,p≤0.001。
  • APD组较PD及健康对照血NfL升高,p<0.001。

临床怎么用

  • 血NfL可作为辅助生物标志物,帮助鉴别PD与APD,尤其适用于需无创检测的场景。
  • 在初级保健和专科诊所中,血NfL可能被纳入帕金森症状患者的诊断检查流程。
  • 对病程≤3年的早期患者,血NfL仍具有区分PD与APD的诊断价值。

局限性

  • 本研究提供Class III证据,证据等级有限。
  • 原文未报告各队列具体纳入排除标准及NfL检测的阈值信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders. METHODS: The study included 3 independent prospective cohorts: the Lund (n = 278) and London (n = 117) cohorts, comprising healthy controls and patients with PD, progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), as well as an early disease cohort (n = 109) of patients with PD, PSP, MSA, or CBS with disease duration ≤3 years. Blood NfL concentration was measured using an ultrasensitive single molecule array (Simoa) method, and the diagnostic accuracy to distinguish PD from APD was investigated. RESULTS: We found strong correlations between blood and CSF concentrations of NfL (ρ ≥ 0.73-0.84, p ≤ 0.001). Blood NfL was increased in patients with MSA, PSP, and CBS (i.e., all APD groups) when compared to patients with PD as well as healthy controls in all cohorts (p < 0.001). Furthermore, in the Lund cohort, blood NfL could accurately distinguish PD from APD (area under the curve [AUC] 0.91) with similar results in both the London cohort (AUC 0.85) and the early disease cohort (AUC 0.81). CONCLUSIONS: Quantification of blood NfL concentration can be used to distinguish PD from APD. Blood-based NfL might consequently be included in the diagnostic workup of patients with parkinsonian symptoms in both primary care and specialized clinics. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that blood NfL levels discriminate between PD and APD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hansson O, Janelidze S, Hall S, et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017. PMID: 28179466. doi:10.1212/WNL.0000000000003680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。